Edgewise Therapeutics Stock Buy Hold or Sell Recommendation
| EWTX Stock | USD 32.08 0.12 0.37% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Edgewise Therapeutics is 'Strong Buy'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Edgewise Therapeutics given historical horizon and risk tolerance towards Edgewise Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for Edgewise Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Edgewise Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Edgewise Stock please use our How to Invest in Edgewise Therapeutics guide. In addition, we conduct extensive research on individual companies such as Edgewise and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Edgewise Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Edgewise |
Execute Edgewise Therapeutics Buy or Sell Advice
The Edgewise recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Edgewise Therapeutics. Macroaxis does not own or have any residual interests in Edgewise Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Edgewise Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Buy
Market Performance | Good | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Edgewise Therapeutics Trading Alerts and Improvement Suggestions
| Edgewise Therapeutics is way too risky over 90 days horizon | |
| Edgewise Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (100.16 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Edgewise Therapeutics currently holds about 248.4 M in cash with (91.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.99. | |
| Edgewise Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from investing.com: Edgewise Therapeutics shares get Outperform rating from Evercore ISI on potential |
Edgewise Therapeutics Returns Distribution Density
The distribution of Edgewise Therapeutics' historical returns is an attempt to chart the uncertainty of Edgewise Therapeutics' future price movements. The chart of the probability distribution of Edgewise Therapeutics daily returns describes the distribution of returns around its average expected value. We use Edgewise Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Edgewise Therapeutics returns is essential to provide solid investment advice for Edgewise Therapeutics.
| Mean Return | 0.93 | Value At Risk | -4.7 | Potential Upside | 6.65 | Standard Deviation | 7.53 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Edgewise Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Edgewise Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Edgewise Therapeutics, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Edgewise Therapeutics back and forth among themselves.
| Shares | Braidwell Lp | 2024-09-30 | 2 M | Deerfield Management Co | 2024-09-30 | 1.8 M | State Street Corp | 2024-06-30 | 1.7 M | Goldman Sachs Group Inc | 2024-06-30 | 1.6 M | Geode Capital Management, Llc | 2024-09-30 | 1.6 M | New Leaf Venture Partners, L.l.c. | 2024-09-30 | 1.6 M | Viking Global Investors Lp | 2024-09-30 | 1.5 M | Bellevue Group Ag | 2024-09-30 | 1.4 M | Driehaus Capital Management Llc | 2024-06-30 | 1.3 M | Orbimed Advisors, Llc | 2024-06-30 | 15 M | Ra Capital Management, Llc | 2024-09-30 | 8.9 M |
Edgewise Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Edgewise Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Edgewise Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Edgewise stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.81 | |
β | Beta against Dow Jones | 0.93 | |
σ | Overall volatility | 7.60 | |
Ir | Information ratio | 0.11 |
Edgewise Therapeutics Volatility Alert
Edgewise Therapeutics is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Edgewise Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Edgewise Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Edgewise Therapeutics Fundamentals Vs Peers
Comparing Edgewise Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Edgewise Therapeutics' direct or indirect competition across all of the common fundamentals between Edgewise Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Edgewise Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Edgewise Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Edgewise Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Edgewise Therapeutics to competition |
| Fundamentals | Edgewise Therapeutics | Peer Average |
| Return On Equity | -0.32 | -0.31 |
| Return On Asset | -0.22 | -0.14 |
| Current Valuation | 2.56 B | 16.62 B |
| Shares Outstanding | 94.69 M | 571.82 M |
| Shares Owned By Insiders | 0.46 % | 10.09 % |
| Shares Owned By Institutions | 99.53 % | 39.21 % |
| Number Of Shares Shorted | 6.39 M | 4.71 M |
| Price To Earning | 3.45 X | 28.72 X |
| Price To Book | 6.24 X | 9.51 X |
| EBITDA | (112.81 M) | 3.9 B |
| Net Income | (100.16 M) | 570.98 M |
| Cash And Equivalents | 248.4 M | 2.7 B |
| Cash Per Share | 4.99 X | 5.01 X |
| Total Debt | 5.41 M | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 27.49 X | 2.16 X |
| Book Value Per Share | 5.18 X | 1.93 K |
| Cash Flow From Operations | (91.95 M) | 971.22 M |
| Short Ratio | 7.89 X | 4.00 X |
| Earnings Per Share | (1.50) X | 3.12 X |
| Target Price | 45.86 | |
| Number Of Employees | 108 | 18.84 K |
| Beta | 0.15 | -0.15 |
| Market Capitalization | 3.05 B | 19.03 B |
| Total Asset | 340.04 M | 29.47 B |
| Retained Earnings | (244.76 M) | 9.33 B |
| Working Capital | 310.23 M | 1.48 B |
| Net Asset | 340.04 M |
Note: Acquisition by Behrad Derakhshan of 4800 shares of Edgewise Therapeutics at 1.93 subject to Rule 16b-3 [view details]
Edgewise Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Edgewise . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Edgewise Therapeutics Buy or Sell Advice
When is the right time to buy or sell Edgewise Therapeutics? Buying financial instruments such as Edgewise Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Edgewise Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Target Risk ETFs Thematic Idea Now
Target Risk ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Target Risk ETFs theme has 32 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Target Risk ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Edgewise Stock Analysis
When running Edgewise Therapeutics' price analysis, check to measure Edgewise Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edgewise Therapeutics is operating at the current time. Most of Edgewise Therapeutics' value examination focuses on studying past and present price action to predict the probability of Edgewise Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edgewise Therapeutics' price. Additionally, you may evaluate how the addition of Edgewise Therapeutics to your portfolios can decrease your overall portfolio volatility.